ZOMIG

USDailyMed:Zolmitriptan AU:B3 N02CC03(WHO) AU:S4(Prescription only) /S3CA:℞-onlyUS:℞-only (S)-4-({3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one 139264-17-8Y 60857 60 DB00315Y 54844Y 2FS66TH3YW D00415Y CHEBI:10124Y ChEMBL1185Y DTXSID8045933 Interactive image O=C1OC[C@@H](N1)Cc2ccc3c(c2)c(c[nH]3)CCN(C)C InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1YKey:ULSDMUVEXKOYBU-ZDUSSCGKSA-NY Zolmitriptan, sold under the brand nameZomigamong others, is aserotonergicmedicationwhich is used in the acute treatment ofmigraineattacks with or withoutauraandcluster headaches.It is takenby mouthas aswallowedordisintegratingtabletor as anasal spray. Side effectsinclude tightness in the neck or throat,jaw pain,dizziness,paresthesia,asthenia,somnolence, warm/cold sensations,nausea,chest pressure, anddry mouth.The drug acts as aselectiveserotonin5-HT1Band5-HT1Dreceptoragonist.Structurally, it is atriptanand atryptaminederivative. It waspatentedin 1990 and was approved for medical use in 1997.